Clinical Trials
22 trialsNCT01841736 2026-05-27
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05988918 2026-05-14
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05724108 2026-05-13
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04848337 2026-05-11
PLANE-PC
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05153772 2026-04-15
ALPHAMEDIX02
Orano Med LLC
Phase 2 Active not recruiting
NCT06502977 2026-04-15
DeLLphi-307
Amgen
Phase 2 Active not recruiting
NCT04079712 2026-04-13
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04969887 2026-02-27
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
Phase 2 Active not recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT03891784 2026-01-14
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
Phase 2 Active not recruiting
NCT06232564 2026-01-14
PELICAN
Imperial College London
Phase 2 Active not recruiting
NCT03600233 2025-12-23
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Phase 2 Active not recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05255159 2025-11-17
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
University of Alberta
Phase 2 Active not recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03457948 2025-09-03
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
Phase 2 Active not recruiting
NCT03454763 2024-09-19
LUTHREE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Active not recruiting
NCT02754297 2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT04524208 2024-08-13
CABONEN
University Medical Center Goettingen
Phase 2 Active not recruiting